{
  "ticker": "MYX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02977690",
  "id": "02977690",
  "pages": 7,
  "price_sensitive": false,
  "date": "20250806",
  "time": "1817",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250806/pdf/06mly5kzl52jy6.pdf",
  "summary": "**Substantial Holder Notice (Form 604) \u2013 Key Points:**  \n\n- **Change in Goldman Sachs' Holdings:** Increased voting power in Mayne Pharma Group from **7.21% (5,854,959 shares)** to **8.30% (6,743,487 shares)**.  \n- **Net Purchases:** Goldman Sachs subsidiary (GAUS) executed **significant buy trades**, including:  \n  - **114,692 shares** on 4 August 2025 (A$581,488 consideration).  \n  - **43,410 shares** on 1 August 2025 (A$214,880 consideration).  \n- **Trading Activity:** Active trading from June\u2013August 2025, with mixed buys/sells (detailed in Annexure B).  \n\n**Material Implication:** Increased institutional stake suggests growing confidence or strategic positioning. Monitor for further accumulation.",
  "usage": {
    "prompt_tokens": 4394,
    "completion_tokens": 183,
    "total_tokens": 4577,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-08-06T08:28:14.778355"
}